New drug duo aims to outsmart tough cancers
NCT ID NCT04705818
Summary
This study tested whether combining two drugs—an immunotherapy (durvalumab) and an epigenetic drug (tazemetostat)—could help control advanced solid tumors that are hard to treat. It enrolled 164 adults with specific advanced cancers, including pancreatic, colorectal, and soft-tissue sarcoma. The main goal was to see if the combination could stop or shrink tumors for a meaningful period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU Brest
Brest, 29200, France
-
CHU Poitiers
Poitiers, 86000, France
-
Institut Bergonie
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.